Single amino acid swap expands nanoparticle vaccine approach to influenza viruses

Influenza viruses constantly shapeshift to evade recognition by the immune system. This shapeshifting occurs in critical proteins like hemagglutinin (HA), which controls how the virus attaches to human cells before entering them. Influenza viruses can evade immunity in two major ways: through the gradual accumulation of mutations that make HA harder for the

The top 3

  1. mRNA Vaccine Technology: mRNA vaccines, like those developed for COVID-19, offer rapid design, high efficacy (e.g., Moderna's flu vaccine showed 26.6% higher efficacy than standard shots in adults 50+), and adaptability to new variants by using genetic code to instruct cells to produce antigens.
  2. Live-Attenuated and Inactivated Vaccines: Traditional vaccines, such as live-attenuated (e.g., measles, mumps, rubella) and inactivated (e.g., early influenza, polio), use weakened or killed forms of pathogens to induce immunity, a foundational approach dating back to Edward Jenner's smallpox vaccine in 1796.
  3. Nanoparticle-Based Vaccines: Nanoparticle vaccines, including virus-like particles (VLPs) and lipid nanoparticles, utilize ultrafine structures to deliver antigens, offering advantages such as enhanced stability, improved immunogenicity, and targeted delivery to immune cells.

Sources

Open the full topic